

MARKET REPORT



Transplantation Drug Development Pipeline Review, 2017

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Transplantation Drug Development Pipeline Review, 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Transplantation Drug Development Pipeline Review, 2017

Transplantation Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the transplantation pipeline landscape, specifically covering drugs used to prevent and treat organ rejection and graft-versus-host disease. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), and the rejection of bone, liver, kidney, lung and heart transplants.

Transplant rejection is a complication that can occur after the replacement of a defective host organ with a foreign donor organ. General risks associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Additionally, following a transplant, the immune system may consider the transplanted heart as foreign and mount a response against it, especially if the antigens expressed by the tissues in each do not match. Generally, immunosuppressive drugs are administered simultaneously with the transplant in order to minimize this risk. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

The size of these pipelines ranges from seven products in heart transplantation to 121 in bone marrow transplantation. A wide range of targets, including integrins, chemokine receptors, protein kinases and cadherins are being developed, with no particular class of target predominating in terms of pipeline volume within each indication. However, there is a clear trend towards immune system molecular targets being studied, reflecting the underlying immune-based pathophysiology of these indications.

Scope

- Which companies are the most active within the pipeline for transplantation therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of transplantation therapeutics?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Additional Details

Publisher : GBI Research

Reference :

Number of Pages : 242

Report Format : PDF

Publisher Information :



GBI RESEARCH
GLOBAL BUSINESS INTELLIGENCE

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Transplantation Drug Development Pipeline Review, 2017 [Report Updated: 01-07-2017]

- Table of Contents
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 12
Introduction 14
Transplantation Report Coverage 14
Bone Marrow Transplant Rejection - Overview 14
Graft Versus Host Disease (GVHD) - Overview 14
Liver Transplant Rejection - Overview 14
Kidney Transplant Rejection - Overview 14
Lung Transplant Rejection - Overview 14
Heart Transplant Rejection - Overview 15
Therapeutics Development 16
Bone Marrow Transplant Rejection 16
Graft Versus Host Disease (GVHD) 27
Liver Transplant Rejection 38
Kidney Transplant Rejection 42
Lung Transplant Rejection 48
Heart Transplant Rejection 51
Therapeutics Assessment 52
Bone Marrow Transplant Rejection 52
Graft Versus Host Disease (GVHD) 62
Liver Transplant Rejection 72
Kidney Transplant Rejection 80
Lung Transplant Rejection 88
Heart Transplant Rejection 96
Companies Involved in Therapeutics Development 104
Bone Marrow Transplant Rejection 104
Graft Versus Host Disease (GVHD) 139
Liver Transplant Rejection 170
Kidney Transplant Rejection 173
Lung Transplant Rejection 185
Heart Transplant Rejection 187
Dormant Projects 189
Bone Marrow Transplant Rejection 189
Graft Versus Host Disease (GVHD) 192
Liver Transplant Rejection 195
Kidney Transplant Rejection 196
Lung Transplant Rejection 198
Heart Transplant Rejection 198
Discontinued Products 199
Bone Marrow Transplant Rejection 199
Graft Versus Host Disease (GVHD) 199
Liver Transplant Rejection 200
Kidney Transplant Rejection 200
Product Development Milestones 201
Bone Marrow Transplant Rejection 201
Graft Versus Host Disease (GVHD) 212
Liver Transplant Rejection 223
Kidney Transplant Rejection 225
Lung Transplant Rejection 234
Appendix 241
Methodology 241
Coverage 241
Secondary Research 241
Primary Research 241
Expert Panel Validation 241
Contact Us 241
Disclaimer 242

List Of Tables in Transplantation Drug Development Pipeline Review, 2017 [Report Updated: 01-07-2017]

List of Tables

Number of Products under Development for Bone Marrow Transplant Rejection	16
Number of Products under Development by Companies, Bone Marrow Transplant Rejection	18
Number of Products under Development by Universities/Institutes, Bone Marrow Transplant Rejection	21
Products under Development by Companies, Bone Marrow Transplant Rejection	22
Products under Development by Universities/Institutes, Bone Marrow Transplant Rejection	26
Number of Products under Development for Graft Versus Host Disease (GVHD)	27
Number of Products under Development by Companies, Graft Versus Host Disease (GVHD)	29
Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)	32
Products under Development by Companies, Graft Versus Host Disease (GVHD)	33
Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)	37
Number of Products under Development for Liver Transplant Rejection	38
Number of Products under Development by Companies, Liver Transplant Rejection	39
Number of Products under Development by Universities/Institutes, Liver Transplant Rejection	40
Products under Development by Companies, Liver Transplant Rejection	41
Products under Development by Universities/Institutes, Liver Transplant Rejection	41
Number of Products under Development for Kidney Transplant Rejection	42
Number of Products under Development by Companies, Kidney Transplant Rejection	44
Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection	45
Products under Development by Companies, Kidney Transplant Rejection	46
Products under Development by Universities/Institutes, Kidney Transplant Rejection	47
Number of Products under Development for Lung Transplant Rejection	48
Number of Products under Development by Companies, Lung Transplant Rejection	49
Products under Development by Companies, Lung Transplant Rejection	50
Number of Products under Development for Heart Transplant Rejection	51
Number of Products under Development by Companies, Heart Transplant Rejection	51
Products under Development by Companies, Heart Transplant Rejection	51
Number of Products by Stage and Target, Bone Marrow Transplant Rejection	53

Number of Products by Stage and Mechanism of Action, Bone Marrow Transplant Rejection 56

Number of Products by Stage and Route of Administration, Bone Marrow Transplant Rejection 59

Number of Products by Stage and Molecule Type, Bone Marrow Transplant Rejection 61

Number of Products by Stage and Target, Graft Versus Host Disease (GVHD) 63

Number of Products by Stage and Mechanism of Action, Graft Versus Host Disease (GVHD) 66

Number of Products by Stage and Route of Administration, Graft Versus Host Disease (GVHD) 69

Number of Products by Stage and Molecule Type, Graft Versus Host Disease (GVHD) 71

Number of Products by Stage and Target, Liver Transplant Rejection 73

Number of Products by Stage and Mechanism of Action, Liver Transplant Rejection 75

Number of Products by Stage and Route of Administration, Liver Transplant Rejection 77

Number of Products by Stage and Molecule Type, Liver Transplant Rejection 79

Number of Products by Stage and Target, Kidney Transplant Rejection 81

Number of Products by Stage and Mechanism of Action, Kidney Transplant Rejection 83

Number of Products by Stage and Route of Administration, Kidney Transplant Rejection 85

Number of Products by Stage and Molecule Type, Kidney Transplant Rejection 87

Number of Products by Stage and Target, Lung Transplant Rejection 89

Number of Products by Stage and Mechanism of Action, Lung Transplant Rejection 91

Number of Products by Stage and Route of Administration, Lung Transplant Rejection 93

Number of Products by Stage and Molecule Type, Lung Transplant Rejection 95

Number of Products by Stage and Target, Heart Transplant Rejection 97

Number of Products by Stage and Mechanism of Action, Heart Transplant Rejection 99

Number of Products by Stage and Route of Administration, Heart Transplant Rejection 101

Number of Products by Stage and Molecule Type, Heart Transplant Rejection 103

Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc 104

Bone Marrow Transplant Rejection - Pipeline by AbGenomics International Inc 104

Bone Marrow Transplant Rejection - Pipeline by Actelion Ltd 105

Bone Marrow Transplant Rejection - Pipeline by Alexion Pharmaceuticals Inc 105

Bone Marrow Transplant Rejection - Pipeline by Allergan Plc 106

Bone Marrow Transplant Rejection - Pipeline by Amunix Operating Inc 106

Bone Marrow Transplant Rejection - Pipeline by AnaptysBio Inc 107

Bone Marrow Transplant Rejection - Pipeline by apceth Biopharma GmbH 107

Bone Marrow Transplant Rejection - Pipeline by Aptevo Therapeutics Inc 108

Bone Marrow Transplant Rejection - Pipeline by arGEN-X BV 108

Bone Marrow Transplant Rejection - Pipeline by Athersys Inc 109

Bone Marrow Transplant Rejection - Pipeline by Bellicum Pharmaceuticals Inc 109

Bone Marrow Transplant Rejection - Pipeline by Bio-Cancer Treatment International Ltd 110

Bone Marrow Transplant Rejection - Pipeline by Biogen Inc 110

Bone Marrow Transplant Rejection - Pipeline by Bristol-Myers Squibb Company 111

Bone Marrow Transplant Rejection - Pipeline by Cantex Pharmaceuticals Inc 111

Bone Marrow Transplant Rejection - Pipeline by Capricor Therapeutics Inc 112

Bone Marrow Transplant Rejection - Pipeline by Cell Source Inc 112

Bone Marrow Transplant Rejection - Pipeline by Cell2B Advanced Therapeutics SA 113

Bone Marrow Transplant Rejection - Pipeline by CelLECT Bio Inc 113

Bone Marrow Transplant Rejection - Pipeline by Cleveland BioLabs Inc 114

Bone Marrow Transplant Rejection - Pipeline by Compugen Ltd 114

Bone Marrow Transplant Rejection - Pipeline by Cynata Therapeutics Limited 115

Bone Marrow Transplant Rejection - Pipeline by Cytodyn Inc 115

Bone Marrow Transplant Rejection - Pipeline by Dompe Farmaceutici SpA 116

Bone Marrow Transplant Rejection - Pipeline by Dr. Falk Pharma GmbH 116

Bone Marrow Transplant Rejection - Pipeline by Escape Therapeutics Inc 117

Bone Marrow Transplant Rejection - Pipeline by F. Hoffmann-La Roche Ltd 117

Bone Marrow Transplant Rejection - Pipeline by Fate Therapeutics Inc 118

Bone Marrow Transplant Rejection - Pipeline by Generon (Shanghai) Corp Ltd 118

Bone Marrow Transplant Rejection - Pipeline by Gilead Sciences Inc 119

Bone Marrow Transplant Rejection - Pipeline by GlaxoSmithKline Plc 119

Bone Marrow Transplant Rejection - Pipeline by Immunomedics Inc 120

Bone Marrow Transplant Rejection - Pipeline by Incyte Corp 120

Bone Marrow Transplant Rejection - Pipeline by Jazz Pharmaceuticals Plc 121

Bone Marrow Transplant Rejection - Pipeline by Kadmon Corp LLC 121

Bone Marrow Transplant Rejection - Pipeline by Kamada Ltd 122

Bone Marrow Transplant Rejection - Pipeline by Kiadis Pharma NV 122

Bone Marrow Transplant Rejection - Pipeline by Kymab Ltd 123

Bone Marrow Transplant Rejection - Pipeline by Kyorin Pharmaceutical Co Ltd 123

Bone Marrow Transplant Rejection - Pipeline by MacroGenics Inc 124

Bone Marrow Transplant Rejection - Pipeline by Mallinckrodt Plc 124

Bone Marrow Transplant Rejection - Pipeline by Medsenic 125

Bone Marrow Transplant Rejection - Pipeline by Mesoblast Ltd 125

Bone Marrow Transplant Rejection - Pipeline by Millennium Pharmaceuticals Inc 126

Bone Marrow Transplant Rejection - Pipeline by Nektar Therapeutics 126

Bone Marrow Transplant Rejection - Pipeline by Neovii Pharmaceuticals AG 127

Bone Marrow Transplant Rejection - Pipeline by Nohla Therapeutics Inc 127

Bone Marrow Transplant Rejection - Pipeline by Novartis AG 128

Bone Marrow Transplant Rejection - Pipeline by Oncolmmune Inc 128

Bone Marrow Transplant Rejection - Pipeline by OSE Immunotherapeutics 129

Bone Marrow Transplant Rejection - Pipeline by Pfizer Inc 129

Bone Marrow Transplant Rejection - Pipeline by Pharmicell Co Ltd 130

Bone Marrow Transplant Rejection - Pipeline by Pluristem Therapeutics Inc 130

Bone Marrow Transplant Rejection - Pipeline by REGiMMUNE Corp 131

Bone Marrow Transplant Rejection - Pipeline by Sanofi 131

Bone Marrow Transplant Rejection - Pipeline by Sarepta Therapeutics Inc 132

Bone Marrow Transplant Rejection - Pipeline by Seattle Genetics Inc 132

Bone Marrow Transplant Rejection - Pipeline by Seres Therapeutics Inc 133

Bone Marrow Transplant Rejection - Pipeline by Sigmoid Pharma Ltd 133

Bone Marrow Transplant Rejection - Pipeline by Synedgen Inc 134

Bone Marrow Transplant Rejection - Pipeline by Taiga Biotechnologies Inc 134

Bone Marrow Transplant Rejection - Pipeline by Takeda Pharmaceutical Company Ltd 135

Bone Marrow Transplant Rejection - Pipeline by Targazyme Inc 135

Bone Marrow Transplant Rejection - Pipeline by United BioPharma Inc 136

Bone Marrow Transplant Rejection - Pipeline by Vault Pharma Inc 136

Bone Marrow Transplant Rejection - Pipeline by VBI Vaccines Inc 137

Bone Marrow Transplant Rejection - Pipeline by Xenikos BV 137

Bone Marrow Transplant Rejection - Pipeline by XL-protein GmbH 138

Bone Marrow Transplant Rejection - Pipeline by ZIOPHARM Oncology Inc 138

Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc 139

Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc 139

Graft Versus Host Disease (GVHD) - Pipeline by Allergan Plc 140

Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc 140

Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc 141

Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH 141

Graft Versus Host Disease (GVHD) - Pipeline by Aptevo Therapeutics Inc 142

Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV 142

Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc 143

Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc 143

Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Ltd 144

Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc 144

Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company 145

Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc 145

Graft Versus Host Disease (GVHD) - Pipeline by Cell2B Advanced Therapeutics SA 146

Graft Versus Host Disease (GVHD) - Pipeline by CELLECT Bio Inc 146

Graft Versus Host Disease (GVHD) - Pipeline by Commence Bio Inc 147

Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd 147

Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc 148

Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH 148

Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics Inc 149

Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd 149

Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc 150

Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corp Ltd 150

Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences Inc 151

Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc 151

Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp 152

Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals Plc 152

Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corp LLC 153

Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd 153

Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma NV 154

Graft Versus Host Disease (GVHD) - Pipeline by Kymab Ltd 154

Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co Ltd 155

Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics Inc 155

Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc 156

Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Ltd 156

Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc 157

Graft Versus Host Disease (GVHD) - Pipeline by Nektar Therapeutics 157

Graft Versus Host Disease (GVHD) - Pipeline by Nohla Therapeutics Inc 158

Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG 158

Graft Versus Host Disease (GVHD) - Pipeline by Oncolmmune Inc 159

Graft Versus Host Disease (GVHD) - Pipeline by OSE Immunotherapeutics 159

Graft Versus Host Disease (GVHD) - Pipeline by Pfizer Inc 160

Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co Ltd 160

Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corp 161

Graft Versus Host Disease (GVHD) - Pipeline by Sanofi 161

Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics Inc 162

Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics Inc 162

Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics Inc 163

Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Ltd 163

Graft Versus Host Disease (GVHD) - Pipeline by Synedgen Inc 164

Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Company Ltd 164

Graft Versus Host Disease (GVHD) - Pipeline by Targazyme Inc 165

Graft Versus Host Disease (GVHD) - Pipeline by TC BioPharm Ltd 165

Graft Versus Host Disease (GVHD) - Pipeline by TxCell SA 166

Graft Versus Host Disease (GVHD) - Pipeline by United BioPharma Inc 166

Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc 167

Graft Versus Host Disease (GVHD) - Pipeline by VBI Vaccines Inc 167

Graft Versus Host Disease (GVHD) - Pipeline by Xenikos BV 168

Graft Versus Host Disease (GVHD) - Pipeline by XL-protein GmbH 168

Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology Inc 169

Liver Transplant Rejection - Pipeline by Astellas Pharma Inc 170

Liver Transplant Rejection - Pipeline by Biogen Inc 170

Liver Transplant Rejection - Pipeline by Conatus Pharmaceuticals Inc 171

Liver Transplant Rejection - Pipeline by Dompe Farmaceutici SpA 171

Liver Transplant Rejection - Pipeline by Novartis AG 172

Liver Transplant Rejection - Pipeline by RedHill Biopharma Ltd 172

Kidney Transplant Rejection - Pipeline by Amgen Inc 173

Kidney Transplant Rejection - Pipeline by Angion Biomedica Corp 173

Kidney Transplant Rejection - Pipeline by Apellis Pharmaceuticals Inc 174

Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc 174

Kidney Transplant Rejection - Pipeline by Biogen Inc 175

Kidney Transplant Rejection - Pipeline by Catalyst Biosciences Inc 175

Kidney Transplant Rejection - Pipeline by Corline Biomedical AB 176

Kidney Transplant Rejection - Pipeline by CSL Ltd 176

Kidney Transplant Rejection - Pipeline by GlaxoSmithKline Plc 177

Kidney Transplant Rejection - Pipeline by Grifols SA 177

Kidney Transplant Rejection - Pipeline by Hansa Medical AB 178

Kidney Transplant Rejection - Pipeline by Kyowa Hakko Kirin Co Ltd 178

Kidney Transplant Rejection - Pipeline by Magnus Life Ltd 179

Kidney Transplant Rejection - Pipeline by Noorik Biopharmaceuticals AG 179

Kidney Transplant Rejection - Pipeline by Novartis AG 180

Kidney Transplant Rejection - Pipeline by Opsona Therapeutics Ltd 180

Kidney Transplant Rejection - Pipeline by OSE Immunotherapeutics 181

Kidney Transplant Rejection - Pipeline by Pharmicell Co Ltd 181

Kidney Transplant Rejection - Pipeline by Pharming Group NV 182

Kidney Transplant Rejection - Pipeline by Prolong Pharmaceuticals LLC 182

Kidney Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc 183

Kidney Transplant Rejection - Pipeline by Shire Plc 183

Kidney Transplant Rejection - Pipeline by Tiziana Life Sciences Plc 184

Lung Transplant Rejection - Pipeline by Apeptico Forschung und Entwicklung GmbH 185

Lung Transplant Rejection - Pipeline by Dompe Farmaceutici SpA 185

Lung Transplant Rejection - Pipeline by Kamada Ltd 186

Lung Transplant Rejection - Pipeline by Novartis AG 186

Lung Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc 187

Heart Transplant Rejection - Pipeline by Astellas Pharma Inc 187

Heart Transplant Rejection - Pipeline by Heat Biologics Inc 188

Heart Transplant Rejection - Pipeline by Noxxon Pharma AG 188

Bone Marrow Transplant Rejection - Dormant Projects 189

Graft Versus Host Disease (GVHD) - Dormant Projects 192

Liver Transplant Rejection - Dormant Projects 195

Kidney Transplant Rejection - Dormant Projects 196

Lung Transplant Rejection - Dormant Projects 198

Heart Transplant Rejection - Dormant Projects 198

Bone Marrow Transplant Rejection - Discontinued Products 199

Graft Versus Host Disease (GVHD) - Discontinued Products 199

Liver Transplant Rejection - Discontinued Products 200

Kidney Transplant Rejection - Discontinued Products 200

List Of Figures, Charts and Diagrams in Transplantation Drug Development Pipeline Review, 2017 [Report Updated: 01-07-2017]

List of Figures

Number of Products under Development for Bone Marrow Transplant Rejection	16
Number of Products under Development by Companies, Bone Marrow Transplant Rejection	17
Number of Products under Development by Universities/Institutes, Bone Marrow Transplant Rejection	20
Number of Products under Development for Graft Versus Host Disease (GVHD)	27
Number of Products under Development by Companies, Graft Versus Host Disease (GVHD)	28
Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)	31
Number of Products under Development for Liver Transplant Rejection	38
Number of Products under Development by Companies, Liver Transplant Rejection	39
Number of Products under Development by Universities/Institutes, Liver Transplant Rejection	40
Number of Products under Development for Kidney Transplant Rejection	42
Number of Products under Development by Companies, Kidney Transplant Rejection	43
Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection	45
Number of Products under Development for Lung Transplant Rejection	48
Number of Products under Development by Companies, Lung Transplant Rejection	49
Number of Products by Top 10 Targets, Bone Marrow Transplant Rejection	52
Number of Products by Stage and Top 10 Targets, Bone Marrow Transplant Rejection	52
Number of Products by Top 10 Mechanism of Actions, Bone Marrow Transplant Rejection	55
Number of Products by Stage and Top 10 Mechanism of Actions, Bone Marrow Transplant Rejection	55
Number of Products by Routes of Administration, Bone Marrow Transplant Rejection	58
Number of Products by Stage and Routes of Administration, Bone Marrow Transplant Rejection	58
Number of Products by Top 10 Molecule Types, Bone Marrow Transplant Rejection	60
Number of Products by Stage and Top 10 Molecule Types, Bone Marrow Transplant Rejection	60
Number of Products by Top 10 Targets, Graft Versus Host Disease (GVHD)	62
Number of Products by Stage and Top 10 Targets, Graft Versus Host Disease (GVHD)	62
Number of Products by Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD)	65
Number of Products by Stage and Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD)	65

Number of Products by Routes of Administration, Graft Versus Host Disease (GVHD) 68

Number of Products by Stage and Routes of Administration, Graft Versus Host Disease (GVHD) 68

Number of Products by Top 10 Molecule Types, Graft Versus Host Disease (GVHD) 70

Number of Products by Stage and Top 10 Molecule Types, Graft Versus Host Disease (GVHD) 70

Number of Products by Top 10 Targets, Liver Transplant Rejection 72

Number of Products by Stage and Top 10 Targets, Liver Transplant Rejection 72

Number of Products by Top 10 Mechanism of Actions, Liver Transplant Rejection 74

Number of Products by Stage and Top 10 Mechanism of Actions, Liver Transplant Rejection 74

Number of Products by Routes of Administration, Liver Transplant Rejection 76

Number of Products by Stage and Routes of Administration, Liver Transplant Rejection 76

Number of Products by Molecule Types, Liver Transplant Rejection 78

Number of Products by Stage and Molecule Types, Liver Transplant Rejection 78

Number of Products by Top 10 Targets, Kidney Transplant Rejection 80

Number of Products by Stage and Top 10 Targets, Kidney Transplant Rejection 80

Number of Products by Top 10 Mechanism of Actions, Kidney Transplant Rejection 82

Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Transplant Rejection 82

Number of Products by Routes of Administration, Kidney Transplant Rejection 84

Number of Products by Stage and Routes of Administration, Kidney Transplant Rejection 84

Number of Products by Top 10 Molecule Types, Kidney Transplant Rejection 86

Number of Products by Stage and Top 10 Molecule Types, Kidney Transplant Rejection 86

Number of Products by Targets, Lung Transplant Rejection 88

Number of Products by Stage and Targets, Lung Transplant Rejection 88

Number of Products by Top 10 Mechanism of Actions, Lung Transplant Rejection 90

Number of Products by Stage and Top 10 Mechanism of Actions, Lung Transplant Rejection 90

Number of Products by Routes of Administration, Lung Transplant Rejection 92

Number of Products by Stage and Routes of Administration, Lung Transplant Rejection 92

Number of Products by Molecule Types, Lung Transplant Rejection 94

Number of Products by Stage and Molecule Types, Lung Transplant Rejection 94

Number of Products by Targets, Heart Transplant Rejection 96

Number of Products by Stage and Targets, Heart Transplant Rejection 96

Number of Products by Mechanism of Actions, Heart Transplant Rejection 98

Number of Products by Stage and Mechanism of Actions, Heart Transplant Rejection 98

Number of Products by Routes of Administration, Heart Transplant Rejection 100

Number of Products by Stage and Routes of Administration, Heart Transplant Rejection 100

Number of Products by Molecule Types, Heart Transplant Rejection 102

Number of Products by Stage and Routes of Administration, Heart Transplant Rejection 102

How to Buy...

Transplantation Drug Development Pipeline Review, 2017 [Report Updated: 01-07-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/100094>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3995** | Single User Price
- \$7990** | Site License Price
- \$11985** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.